ArticlePharmacoEconomics - open2022

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.

Björn Eliasson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.